Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
68 participants
INTERVENTIONAL
2015-09-30
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators used SLEDAI (systemic lupus erythematous disease activity index ) questionnaire for evaluating the clinical signs of the disease. The questionnaires filled out at baseline and after 3 month.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Cell Subsets in SLE Patients Treated with Telitacicept
NCT06677801
Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)
NCT06458972
Effect of Curcumin on Systemic Lupus Erythematosus
NCT03953261
Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus
NCT06137053
The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis
NCT02954939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
green tea extract
Patients were given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules (500 mg) for three months.
green tea extract
Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
Placebo
Patients in placebo group received daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
placebo
Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
green tea extract
Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
placebo
Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Cardiovascular disease
* Patients with infectious or liver disease;
* severe infection
* Pregnancy
* Breastfeeding
* Smoking
* Alcohol consumption
* Use of any dietary supplements
* Changing of medication during the study period
15 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ahvaz Jundishapur University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
zahra shamekhi
zahra shamekhi , phd student in Ahvaz Jundishapur University of Medical Sciences
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iran Ahvaz
Role: PRINCIPAL_INVESTIGATOR
Ahvaz University of Medical Sceinces, Ahvaz, Iran
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Iran
Shiraz, Fars, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IR.AJUMS.REC.1394.251
Identifier Type: OTHER
Identifier Source: secondary_id
IR.AJUMS.REC.1394.251
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.